- Galapagos ( NASDAQ: GLPG ) stock fell ~5% on July 25 after Jefferies Financial downgraded the stock to Underperform from Hold.
- The firm took the action citing challenges facing the Belgium company's base business and the challenges the biotech faces in rebuilding its pipeline.
- In an effort to diversify its pipeline the company announced in June the acquisition of CAR-T therapy developer CellPoint, and AboundBio, a company with a fully human antibody-based library.
- The SA Quant Rating on GLPG is Strong Buy which takes into account factors such as growth and profitability, among others things. Meanwhile, the average Wall Street Analysts' Rating on the stock is Buy , wherein 4 out of 7 analysts give it a Hold, 2 Buy and 1 Strong Buy rating.
- YTD, Galapagos stock has shed ~5% , better than the broader market indicator SP500TR and several peers. See chart here .
For further details see:
Galapagos stock dips after Jefferies slashes rating citing challenges ahead